22785-43-9

Basic information

• Product Name: S-3-N-Cbz-amino-2,6-Dioxo-piperidine
• Synonyms: S-3-N-Cbz-amino-2,6-Dioxo-piperidine;(S)-benzyl 2,6-dioxopiperidin-3-ylcarbamate;REF DUPL: S-3-N-Cbz-amino-2,6-Dioxo-piperidine;(-)-2,6-Dioxo-3-piperidinecarbamic acid benzyl ester;(S)-3-Cbz-amino-2,6-dioxopiperidine
• CAS NO: 22785-43-9
• Molecular Formula: C₁₃H₁₄N₂O₄
• Molecular Weight: 262.26
• Mol File: 22785-43-9.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 520.2°Cat760mmHg
• Flash Point: 268.4°C
• Appearance: /
• Density: 1.31g/cm³
• Vapor Pressure: 6.37E-11mmHg at 25°C
• Refractive Index: 1.58
• CAS DataBase Reference: S-3-N-Cbz-amino-2,6-Dioxo-piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: S-3-N-Cbz-amino-2,6-Dioxo-piperidine(22785-43-9)
• EPA Substance Registry System: S-3-N-Cbz-amino-2,6-Dioxo-piperidine(22785-43-9)

Safety Data

• Hazardous Substances Data: 22785-43-9(Hazardous Substances Data)

Usage

Uses

(S)-Benzyl (2,6-dioxopiperidin-3-yl)carbamate is used in preparation of Lenalidomide and intermediate for its synthesis.

InChI:InChI=1/C13H14N2O4/c16-11-7-6-10(12(17)15-11)14-13(18)19-8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,14,18)(H,15,16,17)/t10-/m0/s1

Upstream product

• 56-85-9 L-glutamine 
• 501-53-1 benzyl chloroformate 
• 1155-62-0 N-benzyloxycarbonyl-L-glutamic acid 
• 2650-64-8 Cbz-L-Gln 
• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 67-56-1 methanol 

Downstream Products

• 202271-89-4 (R)-(+)-4-amino-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3-dione 
• 202271-89-4 (S)-(-)-4-amino-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3-dione 
• 19171-18-7 4-NT 
• 1314881-81-6 padanamide B 
• 1426657-05-7 C₃₇H₆₀N₆O₉Si 
• 492-87-5 N-[(3S)-2,6-dioxo-1-(2-phenylethyl)-3-piperidinyl]-(2S)-2-methylbutanamide 
• 1356018-29-5 (S)-N-((S)-2,6-dioxo-1-phenethylpiperidin-3-yl)-2-methyl-N-(2-oxo-2-(4-oxo-4-(pyren-1-ylmethylamino)butylamino)ethyl)butanamide 
• 1356018-27-3 4-(2-((S)-N-((S)-2,6-dioxo-1-phenethylpiperidin-3-yl)-2-methylbutanamido)acetamido)butanoic acid 
• 1356018-26-2 benzyl 4-(2-((S)-N-((S)-2,6-dioxo-1-phenethylpiperidin-3-yl)-2-methylbutanamido)acetamido)butanoate 
• 1356018-37-5 tert-butyl (2S,3S)-1-((2-(tert-butylamino)-2-oxoethyl) ((S)-2,6-dioxo-1-phenethylpiperidin-3-yl)amino)-3-methyl-1-oxopentan-2-ylcarbamate 
• 1356018-36-4 tert-butyl (S)-1-((2-(tert-butylamino)-2-oxoethyl) ((S)-2,6-dioxo-1-phenethylpiperidin-3-yl)amino)-1-oxo-3-phenylpropan-2-ylcarbamate 
• 1356018-35-3 tert-butyl (S)-1-((2-(tert-butylamino)-2-oxoethyl) ((S)-2,6-dioxo-1-phenethylpiperidin-3-yl)amino)-4-methyl-1-oxopentan-2-ylcarbamate 
• 1356018-34-2 tert-butyl (S)-1-((2-(tert-butylamino)-2-oxoethyl) ((S)-2,6-dioxo-1-phenethylpiperidin-3-yl)amino)-3-methyl-1-oxobutan-2-ylcarbamate 
• 1356018-33-1 tert-butyl (S)-1-((2-(tert-butylamino)-2-oxoethyl) ((S)-2,6-dioxo-1-phenethylpiperidin-3-yl)amino)-1-oxopropan-2-ylcarbamate 

Relevant articles and documents

Preparation method of deuterated intermediate

The present invention provides a preparation method of a deuterated intermediate. The deuterated intermediate has a structure shown by a formula I; the preparation method comprises the following steps: amino groups in a raw material A and an aldehyde grou

METHODS FOR THE TREATMENT OF LOCALLY ADVANCED BREAST CANCER

Provided herein are methods of treating, preventing and/or managing locally advanced breast cancer, including inflammatory breast cancer, which comprise administering to a patient one or more immunomodulatory compounds or enantiomers or mixtures of enantiomers thereof, or pharmaceutically acceptable salts, solvates, hydrates, co-crystals, clathrates, or polymorphs thereof.

Synthesis of (-)-julocrotine and a diversity oriented Ugi-approach to analogues and probes

An improved total synthesis of (-)-julocrotine in three steps from Cbz-glutamine, in 51% overall yield, is presented. To demonstrate the potential of the heterocyclic moiety for diversity oriented synthesis, a series of (-)-julocrotine analogues was synthesized by employing the heterocyclic precursor as an amino input in Ugi four-component reactions (Ugi-4CR) [1].